Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Blanke

Showing results (121-130 of 152) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyRoy S Herbst, Mary W Redman, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
International Journal of Cancer|July 29, 2022
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405Erin L Van Blarigan, Chao Ma, Fang-Shu Ou, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
JAMA Oncology|September 17, 2020
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal CancerChristopher Mackintosh, Chen Yuan, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2026
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical TrialsAllison Booth, Shauna Hillman, Kristina Laumann, et al.
Pageof 16

Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyRoy S Herbst, Mary W Redman, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
International Journal of Cancer|July 29, 2022
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405Erin L Van Blarigan, Chao Ma, Fang-Shu Ou, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
JAMA Oncology|September 17, 2020
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal CancerChristopher Mackintosh, Chen Yuan, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2026
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical TrialsAllison Booth, Shauna Hillman, Kristina Laumann, et al.
Pageof 16